30 closest matches · ranked by relevance
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
Chronic Kidney Disease
Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
End Stage Renal Disease · Anemia
Primary: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only — 4; 8; 7; 4 Participants — p=1.0000
End-stage Renal Disease · Cardiovascular Disease
Primary: Pharmacokinetic Parameters of Ranolazine — 0.65 mcg/mL
CKD Anemia in Stable Dialysis Patients
Primary: US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy — 10.30; 10.31; 0.39…
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Treatment — 39.5; 34.9 percentage of participants — p=0.6746
Autosomal Dominant Polycystic Kidney Disease
Primary: Primary Efficacy Analysis of Total Kidney Volume (mITT Set, Multiple Imputation) — 230.1; 300.8 mL
Hyperphosphatemia · End-stage Renal Disease · Renal Failure Chronic Requiring Hemodialysis
Primary: The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period. — -1.53 mg/dL
End Stage Renal Disease · Kidney Failure · Renal Failure
Primary: Safety Parameters — 142; 35; 75; 0 participants
Hepatitis C
Primary: Sustained Virologic Response (SVR12) Rate — 38 Participants
Kidney Disease, End-Stage
Primary: Symptoms - Trajectory of Change — 77.2; 76.2 score on a scale — p=0.30
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
Kidney Failure, Chronic
Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324
Chronic Kidney Disease
Primary: Factors That Are Most Important to Patients — 98; 93; 97; 100 % of patients
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
End-stage Renal Disease
Primary: F2-isoprostane (F2-iso) — 0.077; 0.073 ng/ml — p=>0.05
End Stage Renal Disease
Primary: Dyad Congruence on Goals-of-Care Tool — 98; 76; 133; 119 dyads
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Anemia in Incident Dialysis Patients
Primary: US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)…
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
Renal Failure
Primary: Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death) — 396; 408 Participants
End Stage Renal Disease
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL — 262; 41 Participants — p=<0.001
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Primary: Cumulative Excretion of Radioactivity — 35.29; 24.26; 0.75; 2.40 Percentage of administered dose